Colorectal cancer screening;Cribado del cáncer colorrectal

Gastroenterologia y Hepatologia

Volumn 34, Issue SUPPL. 1, 2011, Pages 59-63

  Castells, Antoni ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adenoma; Colorectal cancer; Screening; Secondary prevention

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGICAL TECHNIQUE; OCCULT BLOOD; OCCULT BLOOD TEST; PERIODICITY; SIGMOIDOSCOPY; UNITED KINGDOM;

EID: 78650984127     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/S0210-5705(11)70009-7     Document Type: Article

References (30)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: cancer incidence, mortality and prevalence worldwide. Lyon: IARCPress; 2001. Disponible en: http://www-dep.iarc.fr/globocan/globocan.htm.
2. Ahlquist D.A., Pasha T.M. Clinical aspects of sporadic colorectal cancer. Gastrointestinal cancers 2003, 379-405. Saunders, Philadelphia. A.K. Rustgi (Ed.).
3. Farrington S.M., Tenesa A., Barnetson R., Wiltshire A., Prendergast J., Porteous M., et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005, 77:112-119.
4. Piñol V., Castells A., Andreu M., Castellvi-Bel S., Alenda C., Llor X., et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005, 293:1986-1994.
5. Castells A., Marzo-Castillejo M., Mascort J., Amador F., Andreu M., Bellas B., et al. Guía de práctica clínica en prevención del cáncer colorrectal. Gastroenterol Hepatol 2009, 717:e1-e58.
6. Comisión de la Comunidad Europea. Propuesta de Recomendación del Consejo sobre cribado del cáncer, 2003. Disponible en: http://www.who.int/cancer/nccp/en/ecproposalforcouncilrecommendationes.pdf.
7. Plan integral del cáncer. Detección precoz. Dirección General Agencia de Calidad 2003. Disponible en: http://www.msc.es/Diseno/planesIntegrales/planes_integrales.htm.
8. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993, 328:1365-1371.
9. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecaloccult-blood screening for colorectal cancer. Lancet 1996, 348:1472-1477.
10. Kronborg O., Fenger C., Olsen J., Jorgensen O.D., Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348:1467-1471.
11. Morikawa T., Kato J., Yamaji Y., Wada R., Mitsushima T., Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129:422-428.
12. Van Rossum L.G., Van Rijn A.F., Laheij R.J., Van Oijen M.G., Fockens P., Van Krieken H.H., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008, 135:82-90.
13. Logan R.F., Patnick J., Coleman L., Nickerson C. Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million tests. Gastroenterology 2010, 138:S133.
14. Cole S.R., Lane J.M., Smith A., Morcom J.M., Young G.P. Immunochemical fecal occult blood tests detect earlier stage colorectal cancers. Gastroenterology 2010, 138:S190.
15. Denters M., Deutekom M., Bossuyt P.M., Fockens P., Dekker E. Cancer stage at diagnosis is similar in a first and second round of a FOBT-based screening pilot and in participants and non-participants. Gastroenterology 2010, 138:S133.
16. Denters M., Deutekom M., Bossuyt P.M., Fockens P., Dekker E. Equal advanced neoplasia detection rates in first and second round of a fecal immunochemical test based colorectal cancer screening program. Gastroenterology 2010, 138:S186.
17. Van Turenhout S.T., Oort F.A., Coupe V.M., Van der Hulst R.W., Wesdorp E.C., Larbi I.B., et al. Double versus single sampling of fecal immunochemical tests for colorectal cancer screening; added value or added costs?. Gastroenterology 2010, 138:S185.
18. Van Turenhout S.T., Oort F.A., Coupe V.M., Van der Hulst R.W., Wesdorp E.C., Larbi I.B., et al. Comparing three different strategies of double sampling by fecal immunochemical tests for detection of advanced colorectal neoplasms. Gastroenterology 2010, 138:S134.
19. Van Roon A.K., Wilschut J., Van Ballegooijen M., Kranenburg J.L., Van Vuuren A., Van der Togt-van Leeuwen A.C., et al. Attendance and diagnostic yield of one versus two-sample fecal immunochemical test screening; a comparative population-based colorectal cancer trial. Gastroenterology 2010, 138:S134.
20. Grazzini G., Visioli C.B., Zorzi M., Ciatto S., Banovich F., Bonanomi A.G., et al. Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?. Br J Cancer 2009, 100:259-265.
21. Van Roon A.K., Hol L., Van Leerdam M.E., Van Ballegooijen M., Van Vuuren A., Van der Togt-van Leeuwen A.C., et al. Fecal immunochemical test characteristics by sample return time in a population-based colorectal cancer screening trial. Gastroenterology 2010, 138:S133.
22. Wilschut J., Van Roon A.K., Van Leerdam M.E., Kuipers E.J., Habbema J.D., Van Ballegooijen M. Should we offer individuals two samples of a fecal immunochemical test for colorectal cancer screening instead of one? A cost-effectiveness analyis. Gastroenterology 2010, 138:S183.
23. Wilschut J., Hol L., Dekker E., Jansen J.B., Van Leerdam M.E., Lansdorp-Vogelaar I., et al. Quantitative immunochemical fecal occult blood screening under a colonoscopy constraint: a higher cut-off level, a smaller age range or a longer screening interval? A cost-effectiveness analysis. Gastroenterology 2010, 138:S183.
24. Atkin W., Cuzick J., Duffy S.W., Edwards R., Hart A.R., Kralj-Hans I., et al. UK Flexible Sigmoidoscopy Screening Trial: colorectal cancer incidence and mortality rates at 11 years after a single screening examination. Gastroenterology 2010, 138:S53.
25. Atkin W.S., Edwards R., Kralj-Hans I., Wooldrage K., Hart A.R., Northover J.M., et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010, 375:1624-1633.
26. Selby J.V., Friedman G.D., Quesenberry C.P., Weiss N.S. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992, 326:653-657.
27. Newcomb P.A., Norfleet R.G., Storer B.E., Surawicz T.S., Marcus P.M. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992, 84:1572-1575.
28. Newcomb P.A., Storer B.E., Morimoto L.M., Templeton A., Potter J.D. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003, 95:622-625.
29. Segnan N., Senore C., Andreoni B., Arrigoni A., Bisanti L., Cardelli A., et al. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005, 97:347-357.
30. Senore C., Andreoni B., Armaroli P., Bisanti L., Giacomin A., Giliani J., et al. The added value of immunochemical FOBT following a negative screening sigmoidoscopy. Gastroenterology 2010, 138:S186.